Ependymoma Overview
Learn About Ependymoma
View Main Condition: Brain Tumor
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as an Elite provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.
Duke Cancer Center
Katherine Peters is a Neurologist in Durham, North Carolina. Dr. Peters is rated as a Distinguished provider by MediFind in the treatment of Ependymoma. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Brain Tumor, and Astrocytoma. Dr. Peters is currently accepting new patients.
Duke Cancer Center Brain Tumor Clinic
Allan Friedman is a Neurosurgery provider in Durham, North Carolina. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of Ependymoma. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, Awake Craniotomy, and Laminectomy. Dr. Friedman is currently accepting new patients.
Summary: The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) ne...
Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...


